Overview

Pharmacokinetics, Pharmacodynamics Profile and Tolerance of P03277 in Healthy Subjects and Patients With Brain Lesions

Status:
Completed
Trial end date:
2015-04-17
Target enrollment:
Participant gender:
Summary
The primary objective of this study was to evaluate the safety (clinical and biological) and pharmacokinetics (plasma and urine) profile of P03277 following single administration at ascending dose levels in healthy subjects.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Guerbet